ERBB2 and gastric cancer: In the treatment of HER2-positive gastric cancer, a comparison of the combination of lapatinib with oxaliplatin and capecitabine against capecitabine and oxaliplatin alone revealed OS values of 10.5 months and 12.2 months, and PFS values of 6.0 months and 5.4 months in the respective groups (59).